Related Experiment Videos
A phase II study of Catrix-S in solid tumors.
Journal of Biological Response Modifiers
|December 1, 1985
Summary
Catrix-S, an acidic mucopolysaccharide from bovine cartilage, showed limited efficacy in treating advanced cancers. While one patient with metastatic renal cell carcinoma responded, most experienced disease progression without significant toxicity.
Area of Science:
- Oncology
- Biochemistry
- Pharmacology
Background:
- Acidic mucopolysaccharides, like Catrix-S derived from bovine tracheal cartilage, are investigated for potential therapeutic applications.
- Metastatic malignancy presents a significant challenge in cancer treatment, necessitating novel therapeutic strategies.
Purpose of the Study:
- To evaluate the safety and efficacy of Catrix-S in patients with progressive metastatic malignancy.
- To assess the clinical response and toxicity profile of weekly subcutaneous Catrix-S injections.
Main Methods:
- Nine patients with progressive metastatic malignancy received weekly subcutaneous injections of Catrix-S (5.0-7.5 g/week).
- Clinical outcomes, including tumor response and disease progression, were monitored.
- Toxicity and immunologic alterations were assessed.
Main Results:
- One complete response was observed in a patient with metastatic renal cell carcinoma to the lungs.
- Eight out of nine patients experienced disease progression.
- No undue toxicity or consistent immunologic alterations were noted during the study.
Conclusions:
- Catrix-S demonstrated a limited clinical benefit in this small cohort of patients with advanced metastatic malignancy.
- The observed safety profile suggests a low toxicity risk, but efficacy remains a concern for widespread application.